Your browser doesn't support javascript.
loading
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.
Curti, B D; Longo, D L; Ochoa, A C; Conlon, K C; Smith, J W; Alvord, W G; Creekmore, S P; Fenton, R G; Gause, B L; Holmlund, J.
Affiliation
  • Curti BD; Biological Response Modifiers Program, Program Resources, Inc/DynCorp., Frederick, MD.
J Clin Oncol ; 11(4): 652-60, 1993 Apr.
Article in En | MEDLINE | ID: mdl-8257476
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Killer Cells, Natural / Killer Cells, Lymphokine-Activated / Immunotherapy, Adoptive / Lymphocytes, Tumor-Infiltrating / Interleukin-2 / CD3 Complex / Neoplasms Type of study: Etiology_studies / Guideline Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 1993 Document type: Article Affiliation country: Moldova Country of publication: United States
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Killer Cells, Natural / Killer Cells, Lymphokine-Activated / Immunotherapy, Adoptive / Lymphocytes, Tumor-Infiltrating / Interleukin-2 / CD3 Complex / Neoplasms Type of study: Etiology_studies / Guideline Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 1993 Document type: Article Affiliation country: Moldova Country of publication: United States